ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Roche obtained from European Medicine Agency (EMA) a special authorization (conditional approval) for new bispecific antibody Lunsumio for treatment of relapsed or refractory follicular (R/R) lymphoma (FL) – a B-cell cancer. Data for authorization are based on a survey from a phase I/II trail. The high unmet need of this indication led to that early decision, it is said.
ImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments are invested already. Invus and The Leukemia & Lymphoma
Society Therapy Acceleration Program also joined the round as new investors.
CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology.
Based on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Biotalys’ biocontrol product Evoca provided superior preventative control of Botrytis bunch rot in grapevines compared to chemical standard. Approval is estimated within this year.
Andera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.
Successful restart: From 31 May to 1 June 2022, Chemspec Europe attracted 5,122 industry experts from 57 countries, of which 3,162 were trade visitors. A total of 287 exhibitors from 26 countries presented their product portfolio on a net exhibition space of 5,300 m2 at Messe Frankfurt, Germany. With topics such as sustainable innovations, regulatory compliances, circular bio-economy, green chemistry, digitalisation, and the flourishing startup scene, the 35th International Exhibition for Fine and Speciality Chemicals highlighted insights of current and future developments within the industry.
The South Wales-based demonstration plant "VAMOS" that generates industrial biotechnology sugars and other recycled material streams from the paper and card in mixed household waste has come online these days. The products will be used in the production of several high-performance bio-based materials.
The International Vaccine Institute, IVI, which is associated with the WHO and UN, will locate its European office in Stockholm. To date, the institute is only located in the host country of South Korea.
The financing (around €19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.
Transine Therapeutics Ltd has added £4.6m from lead investor Epidarex Capital and the Dementia Discovery Fund (DDF) to its £9.1m seed funding led by Takeda Ventures and DDF.